Suppr超能文献

肝移植候选者单发小肝细胞癌介入性肝定向治疗的成本效益分析。

Cost-Effectiveness Analysis of Interventional Liver-Directed Therapies for a Single, Small Hepatocellular Carcinoma in Liver Transplant Candidates.

机构信息

Department of Radiology and Biomedical Imaging, Stanford University, San Francisco, California.

Department of Gastroenterology & Hepatology, Stanford University, San Francisco, California.

出版信息

J Vasc Interv Radiol. 2023 Jul;34(7):1237-1246.e3. doi: 10.1016/j.jvir.2023.02.016. Epub 2023 Feb 16.

Abstract

PURPOSE

To assess the cost effectiveness of 3 main locoregional therapies (LRTs) (transarterial chemoembolization [TACE], transarterial radioembolization [TARE], and percutaneous ablation) as bridging therapy.

MATERIALS AND METHODS

A cost-effectiveness analysis was performed comparing the 3 LRTs for patients with a single hepatocellular carcinoma (HCC) with a diameter of 3 cm or less over a 5-year time horizon from a payer's perspective. The clinical courses, including transplantation, decompensation resulting in delisting, and the need for a second LRT, were based on data from the United Network for Organ Sharing (2016-2019). Costs and effectiveness were measured in U.S. dollars and quality-adjusted life-years, respectively. Probabilistic and deterministic sensitivity analyses were performed.

RESULTS

A total of 2,594, 1,576, and 903 patients underwent TACE, ablation, and TARE, respectively. Ablation was the dominant strategy, with the lowest expected cost and highest effectiveness. The probabilistic sensitivity analysis demonstrated that ablation was the most cost-effective strategy in 93.9% of simulations. A subgroup analysis was performed for different wait times, with ablation remaining the most cost-effective strategy. The sensitivity analysis showed that ablation was most effective if the risk of waitlist dropout was less than 2.00% and the rate of transplantation was more than 15.1% quarterly. TARE was most effective if the risk of dropout was less than 1.19% and the rate of transplantation was more than 24.0%. TACE was most effective if the risk of dropout was less than 1.01% and the rate of transplantation was more than 45.7%. Ablation remained the most cost-effective modality until its procedural cost was more than $34,843.

CONCLUSIONS

Ablation is the most cost-effective bridging strategy for patients with a single, small (≤3 cm) HCC prior to liver transplantation. The conclusion remained robust in multiple sensitivity analyses.

摘要

目的

评估 3 种主要局部区域治疗(LRT)(经动脉化疗栓塞[TACE]、经动脉放射性栓塞[TARE]和经皮消融)作为桥接治疗的成本效益。

材料和方法

从支付者的角度出发,在 5 年的时间内,对 3 种 LRT 治疗单个直径≤3cm 的肝细胞癌(HCC)患者进行成本效益分析。临床过程,包括移植、导致除名的失代偿和需要第二次 LRT,基于美国器官共享联合网络的数据(2016-2019 年)。成本和效果分别以美元和美分调整生命年(QALY)衡量。进行了概率和确定性敏感性分析。

结果

共有 2594 例、1576 例和 903 例患者分别接受了 TACE、消融和 TARE。消融是最具成本效益的策略,预期成本最低,效果最高。概率敏感性分析表明,在 93.9%的模拟中,消融是最具成本效益的策略。对不同等待时间进行了亚组分析,消融仍然是最具成本效益的策略。敏感性分析表明,如果候补名单退出的风险小于 2.00%且每季度移植率大于 15.1%,则消融效果最佳。如果退出风险小于 1.19%且移植率大于 24.0%,则 TARE 效果最佳。如果退出风险小于 1.01%且移植率大于 45.7%,则 TACE 效果最佳。消融在其程序成本超过 34843 美元之前,仍然是最具成本效益的方式。

结论

对于单个、小(≤3cm)HCC 患者,在进行肝移植之前,消融是最具成本效益的桥接策略。在多次敏感性分析中,该结论仍然稳健。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验